{
    "nct_id": "NCT03155997",
    "official_title": "A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer",
    "inclusion_criteria": "* Women (regardless of menopausal status) or men ≥18 years of age (or per local regulations).\n* The participant has confirmed HR+, HER2-, early stage resected invasive breast cancer without evidence of distant metastases.\n* The participant must have undergone definitive surgery of the primary breast tumor.\n* The participant must have tumor tissue from breast (preferred) or lymph node for exploratory biomarker analysis available prior to randomization.\n* Pathologic lymph node involvement and at least one of the following indicating a higher risk of recurrence:\n\n  * 4 or more positive axillary lymph nodes\n  * Tumor size of at least 5 centimeters\n  * Grade 3 defined as at least 8 points on the Bloom Richardson grading system\n  * Ki-67 index by central analysis of ≥20% on untreated breast tissue\n* The participant must be randomized within 16 months from the time of definitive breast cancer surgery.\n* The participant may receive up to 12 weeks of endocrine therapy until randomization following the last non-endocrine therapy (surgery, chemotherapy, or radiation) whichever is last.\n* Participants must have recovered (grade ≤1) from the acute effects of chemotherapy and radiotherapy and from surgical side effects following definitive breast surgery.\n* Women of reproductive potential must have a negative blood pregnancy test and agree to use highly effective contraceptive methods.\n* The participant has a Eastern Cooperative Oncology Group (ECOG) performance status ≤1.\n* The participant has adequate organ function.\n* The participant is able to swallow oral medications.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Metastatic disease (including contralateral axillary lymph nodes) or node-negative disease.\n* Participants with inflammatory breast cancer.\n* Participants with a history of previous breast cancer, with the exception of ipsilateral ductal carcinoma in situ (DCIS) treated by locoregional therapy alone ≥5 years ago. Participants with a history of contralateral DCIS treated by local regional therapy at any time may be eligible. Participants with a history of any other cancer (except non-melanoma skin cancer or carcinoma in situ of the cervix), unless in complete remission with no therapy for a minimum of 5 years from the date of randomization are excluded.\n* Females who are pregnant or lactating.\n* The participant has previously received treatment with any CDK4 and CDK6 inhibitor.\n* The participant is receiving concurrent exogenous reproductive hormone therapy (for example, birth control pills, hormone replacement therapy, or megestrol acetate).\n* The participant has previously received endocrine therapy for breast cancer prevention (tamoxifen or aromatase inhibitors) or raloxifene.\n* The participant has serious preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study.\n* The participant has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin or sudden cardiac arrest. Any participant with a history of venous thromboembolism (VTE).\n* The participant has active systemic infections or viral load.\n* The participant has received an experimental treatment in a clinical trial within the last 30 days or 5 half-lives, whichever is longer.",
    "miscellaneous_criteria": ""
}